Genentech Executive Vice President Richard Scheller discusses some of the thought-provoking ethical issues that arise in the drug development process. To illuminate the issue, Scheller describes the painful challenges of the clinical trial placebo process, often required by the Food and Drug Administration. He also articulates some of the ethical implications related to drug costs and insurance reimbursements.
